Affiliations: [a] Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, Hebei, China
| [b] Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, Hebei, China
| [c] Shijiazhuang Obstetrics and Gynecology Hospital, Shijiazhuang, Hebei, China
| [d] Helmholtz-Zentrum Hereon, Institute of Active Polymers, Teltow, Germany
| [e] Institute of Chemistry and Biochemistry, Freie Universität Berlin, Berlin, Germany
| [f] Deutsches Herzzentrum Berlin, Berlin, Germany
| [g] Department of Plastic, Hand and Reconstructive Surgery, University Hospital Regensburg, Regensburg, Germany
Correspondence:
[*]
Corresponding authors. Gang Wang and Jia Nie, Hebei Provincial Hospital of Chinese Medicine, Shijiazhuang, Hebei, China. Tel.: +86 15831164937, E-mail: cpwg732@126.com (Gang Wang); Tel.: +86 13930195185, E-mail: 765583692@qq.com (Jia Nie).
Abstract: Myocardial infarction refers to the ischemic necrosis of myocardium, characterized by a sharp reduction or interruption of blood flow in the coronary arteries due to the coronary artery occlusion, resulting in severe and prolonged ischemia in the corresponding myocardium and ultimately leading to ischemic necrosis of the myocardium. Given its high risk, it is considered as one of the most serious health threats today. In current clinical practice, multiple approaches have been explored to diminish myocardial oxygen consumption and alleviate symptoms, but notable success remains elusive. Accumulated clinical evidence has showed that the implantation of mesenchymal stem cell for treating myocardial infarction is both effective and safe. Nevertheless, there persists controversy and variability regarding the standardizing MSC transplantation protocols, optimizing dosage, and determining the most effective routes of administration. Addressing these remaining issues will pave the way of integration of MSCs as a feasible mainstream cardiac treatment.
